Twenty-eight children took part in a double-blind, placebo-controlled, crossover study of fenfluramine and methylphenidate. Fenfluramine dosage was gradually increased to a standardized dose of 1.5 mg/kg per day, whereas methylphenidate was given in doses of 0.4 mg/kg per day. The children were assessed on laboratory tests of selective and sustained attention, visual matching, and color matching, during which seat activity was monitored automatically. Results showed fenfluramine to be superior to placebo on the memory task, whereas methylphenidate reduced commission errors on a continuous performance test. Methylphenidate caused shorter response times, and fenfluramine caused increases, on two of the tests. Examiner behavior ratings indicated significant improvements with both drugs on the domains of attention, activity level, and mood. These findings, together with those from a companion clinical study, suggest that the drugs may have contrasting mechanisms of action, but both appear to have useful clinical effects in these children.
We performed a randomized nonblinded, cross-over comparison
of patient-controlled analgesia (PCA) with conventional
intramuscular analgesia in 10 adolescents (13-18 years) undergoing
spinal fusion for idiopathic scoliosis. PCA use afforded
more effective pain control (p < 0.02) on a 10-point
linear pain intensity scale than did intramuscular injections,
while causing an equal amount of sedation and no side effects.
PCA appears to be a promising technique for providing postoperative
pain relief in this group of adolescents. Further studies
are needed to define its role for other pediatric conditions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.